ValuEngine lowered shares of Myokardia (NASDAQ:MYOK) from a buy rating to a hold rating in a research note published on Friday.

Several other equities analysts have also commented on the company. BidaskClub lowered Myokardia from a buy rating to a hold rating in a research note on Saturday, January 19th. Zacks Investment Research lowered Myokardia from a buy rating to a hold rating in a research note on Tuesday, January 8th. Credit Suisse Group decreased their price target on Myokardia from $73.00 to $71.00 and set an outperform rating on the stock in a research note on Friday, January 4th. Citigroup decreased their price target on Myokardia from $90.00 to $70.00 and set a buy rating on the stock in a research note on Thursday, January 3rd. Finally, Wedbush reaffirmed an outperform rating and issued a $77.00 price target on shares of Myokardia in a research note on Friday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. Myokardia presently has an average rating of Buy and a consensus price target of $74.64.

NASDAQ MYOK traded up $0.21 on Friday, reaching $40.11. 197,075 shares of the company were exchanged, compared to its average volume of 328,201. The firm has a market capitalization of $1.62 billion, a P/E ratio of -28.65 and a beta of 2.49. Myokardia has a fifty-two week low of $39.16 and a fifty-two week high of $67.79.

Myokardia (NASDAQ:MYOK) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.11. Myokardia had a negative return on equity of 19.40% and a negative net margin of 222.07%. The business had revenue of $9.19 million for the quarter, compared to analyst estimates of $7.57 million. On average, equities research analysts predict that Myokardia will post -1.8 earnings per share for the current fiscal year.

In related news, CEO Anastasios Gianakakos sold 2,770 shares of the firm’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $44.11, for a total transaction of $122,184.70. Following the transaction, the chief executive officer now owns 76,967 shares in the company, valued at approximately $3,395,014.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider June Lee sold 5,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $60.81, for a total value of $304,050.00. The disclosure for this sale can be found here. Insiders have sold a total of 10,770 shares of company stock worth $593,275 in the last 90 days. 4.70% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. FMR LLC lifted its position in Myokardia by 0.5% during the 3rd quarter. FMR LLC now owns 6,017,310 shares of the biotechnology company’s stock worth $392,329,000 after acquiring an additional 27,198 shares during the period. Vanguard Group Inc lifted its position in Myokardia by 32.8% during the 3rd quarter. Vanguard Group Inc now owns 2,995,821 shares of the biotechnology company’s stock worth $195,328,000 after acquiring an additional 740,607 shares during the period. Vanguard Group Inc. lifted its position in Myokardia by 32.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,995,821 shares of the biotechnology company’s stock worth $195,328,000 after acquiring an additional 740,607 shares during the period. BlackRock Inc. lifted its position in Myokardia by 0.3% during the 4th quarter. BlackRock Inc. now owns 2,861,588 shares of the biotechnology company’s stock worth $139,816,000 after acquiring an additional 9,099 shares during the period. Finally, Partner Fund Management L.P. lifted its position in Myokardia by 3.3% during the 3rd quarter. Partner Fund Management L.P. now owns 1,878,909 shares of the biotechnology company’s stock worth $122,505,000 after acquiring an additional 59,594 shares during the period. 88.57% of the stock is owned by institutional investors.

About Myokardia

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression.

Recommended Story: Yield Curve

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.